Myeloablative doses of yttrium‐90‐ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemiaAnna Guidetti, Alessandro M. Gianni, Alessandra Risso et al.|Cancer|2011Cited by 28
Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose <sup>90</sup>Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAMLiliana Devizzi, Alessandro M. Gianni, Corrado Tarella et al.|Journal of Clinical Oncology|2013Cited by 14